title: MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut.
authors.affiliation: Assistente Hospitalar Graduado de Pneumologia, Centro Hospitalar e Universitário de Coimbra, Portugal. Electronic address: fjssbarata@gmail.com.
authors.forename: F
authors.initials: F
authors.lastname: Barata
authors.affiliation: Professor da Faculdade de Medicina do Porto, Assistente Hospitalar Sénior, Centro Hospitalar de S João, Portugal. Electronic address: hjqueiroga@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Queiroga
authors.affiliation: Assistente Hospitalar Graduada de Pneumologia, Centro Hospitalar Lisboa Norte, Portugal. Electronic address: encarnacaoteixeira@gmail.com.
authors.forename: E
authors.initials: E
authors.lastname: Teixeira
authors.affiliation: Assistente Hospitalar Graduada Pneumologia, Instituto Português Oncologia Lisboa Francisco Gentil, Rua Professor Lima, Basto, 1089 Lisboa, Portugal. Electronic address: mteresaasa@gmail.com.
authors.forename: M T
authors.initials: MT
authors.lastname: Almodovar
authors.affiliation: Assistente Hospitalar Sénior de Pneumologia, Centro Hospitalar Gaia/Espinho, Portugal. Electronic address: barbaraparente@gmail.com.
authors.forename: B
authors.initials: B
authors.lastname: Parente
authors.affiliation: Assistente Hospitalar de Oncologia Médica, IPOPORTOFG, Portugal. Electronic address: martasoares71@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Soares
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011174:Portugal; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors